Surgery on Patients Taking Glucagon-Like Peptide-1 Receptor Agonists

Area of Science:

• Endocrinology
• Pharmacology
• Metabolic Diseases

Background:

• Glucagon-like peptide-1 receptor (GLP-1R) agonists have emerged as a significant therapeutic class.
• Their development targets key pathways in type 2 diabetes and obesity management.
• Understanding their historical context and evolution is crucial for appreciating their current role.

Purpose of the Study:

• To provide a comprehensive overview of GLP-1R agonist medications.
• To discuss their mechanism of action, clinical impacts, and approved agents.
• To explore their efficacy in weight loss, use in bariatric surgery, and perioperative management.

Main Methods:

• Literature review of historical data and clinical studies.
• Analysis of Food and Drug Administration (FDA)-approved GLP-1R agonists.
• Synthesis of information on therapeutic effects, weight loss comparisons, and surgical considerations.

Main Results:

• GLP-1R agonists demonstrate significant efficacy in managing type 2 diabetes and promoting weight loss.
• Several FDA-approved agents are available, each with distinct characteristics.
• Comparative data highlights varying effects on weight reduction, with implications for bariatric surgery contexts.

Conclusions:

• GLP-1R agonists represent a cornerstone in modern metabolic disease treatment.
• Careful consideration of their use, especially perioperatively, is essential for patient safety and optimal outcomes.
• Further research may refine their application in diverse clinical scenarios.